Results 71 to 80 of about 12,575 (207)
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial [PDF]
, 2018 International audienceBackgroundThe OPTIPRIM-ANRS 147 trial compared intensive combination ART (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir and maraviroc) started early during primary HIV-1 infection with standard ...Ruquet, M, J M Molina, G Catalano, Simon, A, M Vassallo, S Ben Abdallah, M Parrinello, S Gallien, Naqvi, Alice, Pichon, F, Delfraissy, J, Makinson, A, C Arvieux, L Letranchant, F Fily, S Bonne, T Ferry, Amri, I, Reliquet, V, P Mathurin, M P Bouillon, Thierry, S, Veron, R, D Brosseau, T L'Yavanc, E Braun, Chauveau, M, M Shoai, C Allavena, Prevoteau Du Clary, F, C Katlama, Rami, A, de Lastours, V, D Lacoste, Morquin, D, C Baringhton, Antoine Cheret, Laurent Tran, Y Levy, E Ousseima, Augustin Normand, C, Joulié, A, Rehaiem, S, Laplantine, V, Senechal, A, Philippe Morlat, A Vallon, M Revest, Tassadit, T, Brosseau, D, F Balsarin, I Ravaux, Tourdjman, M, J J Jourdain, Bourdeaux, C, L Slama, F Clavel, H Leroy, Phung, B, A Rami, Pierre-François, S, V Thoirain, M A Valentin, Ponscarme, D, Obadia, M, Etienne, M, Cotte, L, Richier, L, Allavena, C, M Carrerre, Fauchere, V, A Durel, A Chéret, A Adda, J Pavie, Yeni, P, S Ferret, M Môle, Feuillebois, N, I Alcaraz, M Chauveau, Abel, S, Clavel, F, C M Ratajczak, Billaud, E, Hoen, B, P Abgueguen, J Goguel, F Raffi, Delaune, J, Lafeuillade, A, J F Dailloux, S Pierre-François, Môle, M, J Delgado, F Touam, F Brunel Dalmas, C Rioux, Chennebault, J, B Phung, F Borsa Lebas, E Fourn, Carrerre, M, N Viget, Corsini, N, Déborah Hirt, Stenzel, M, Debab, Y, May, T, Caldato, S, l'Yavanc, T, Vandenhende, M, J Lipman, V Reliquet, Cheret, Antoine, V Lambry, S Pailhes, Receveur, M, J Lippran, Raffi, F, A Therby, Lelievre, J, Katlama, C, Neau, D, Lacaze-Buzy, L, M Diemer, Brunet-François, C, V Lemoine, J Koffi, Véronique Avettand-Fenoel, Pressiat, Claire, Koffi, J, C Michaux, Kiorza, N, E Chakvetadze, M P Pietri, E Aissi, Ferry, T, C Goujard, Pialoux, G, Baringhton, C, F Caron, J M Jacquet, Durant, J, Louni, F, V Laplantine, H Hüe, Lascoux, C, N De Castro, Fialaire, P, F Pichon, Meyer, Laurence, Dailloux, J, N Bernard, Alice Naqvi, Rouzioux, Christine, Rioux, C, M Etienne, Loriette, M, W Rozenbaum, Huleux, T, J M Chennebault, Jacquet, J, Balkan, S, Merle, C, M C Receveur, C Brochier, Chapuzet, C, I Gueit, V Berrebi, Livrozet, J, Michaux, C, N Colin De Verdiere, Mathurin, P, Zheng, Yi, Briaud, A, Aissi, E, Shoai, M, C Tramoni, M Stenzel, C Burty, M Pauchard, Pavie, J, G Gras, P Chiarello, Diemer, M, Brochier, C, A Greder Belan, Atoui, N, C Lascoux, F Ajana, P Yeni, de la Tribonniere, X, A Makinson, Quertainmont, Y, Thoirain, V, J M Livrozet, X De La Tribonniere, N Feuillebois, Vassallo, M, M A Vandenhende, C Merle, F Louni, A Simon, D Makhloufi, Fily, F, Slama, L, S Wassoumbou, H Melliez, Allègre, T, F Prevoteau Du Clary, Fourn, E, V Fauchere, P Miailhes, Lascaux, A, I Schlienger, T Huleux, Giovanna, M, Miailhes, P, N Corsini, S Larrigue, A Senechal, Michelet, C, J Delaune, R Veron, Arvieux, C, F Paccalin, O Mounoury, Charlier, C, Balsarin, F, S Seang, A Naqvi, Rozenbaum, W, Lipman, J, S M Thierry, L Lacaze-Buzy, D Morquin, Ben Abdallah, S, Paccalin, F, D Salmon, Monnier, S, Vandamme, Y, null null, Dominguez, S, Schneider, L, L Schneider, Lafaurie, M, Catalano, G, G Pialoux, M Loriette, Valentin, M, B Bonnet, T Perpoint, A Chermak, Ousseima, E, Touam, F, Reynes, J, V Baclet, Bouchez, S, Ravaux, I, Gras, G, Leroy, H, Lippran, J, Biron, F, Dumont, C, Jourdain, J, P Fialaire, M Giovanna, El Alami Talbi, N, Hüe, H, B Marchou, J Durant, Lambry, V, V Garrait, Braun, E, Marchou, B, Poissy, J, Letranchant, L, J Reynes, P Dellamonica, Jean-Paul Viard, T Tassadit, Chidiac, C, S Monnier, I Amri, A Rachline, A Leplatois, Aslan, A, Gueit, I, Revest, M, Bonne, S, Yi Zheng, Hittinger, G, Scemla, A, Gallien, S, Alcaraz, I, Levy, Y, L Cuzin, P Morlat, Molina, J, Jeanblanc, F, Seang, S, Wassoumbou, S, C Chidiac, Berrebi, V, Chakvetadze, E, Goujard, C, C Michelet, Goguel, J, Melliez, H, Borsa Lebas, F, Viard, Jean-Paul, A Lafeuillade, F Biron, Laurence Meyer, V Rabier, A Boibieux, Lemoine, V, F Souala, Y M Vandamme, C Godard, A Briaud, Lacoste, D, Ratajczak, C, L Bernard, Pailhes, S, Hirt, Déborah, J Poissy, Brunel Dalmas, F, C Dumont, Rachline, A, Tramoni, C, Godard, C, Guiroy, F, Jean-Marc Treluyer, Souala, F, M Tourdjman, E Billaud, S Bouchez, Morlat, Philippe, Therby, A, Parrinello, M, Leplatois, A, M Varan, C Duvivier, Rabier, V, Ferret, S, Claire Pressiat, G Philip, N Atoui, Baclet, V, S Dominguez, Garrait, V, Viget, N, Duvivier, C, D Ponscarme, D Neau, Avettand-Fenoel, Véronique, Durel, A, Consigny, P, Delgado, J, V De Lastours, Chiarello, P, Tran, Laurent, Pauchard, M, Vallon, A, Morineau-Le-Houssine, P, Makhloufi, D, A Scemla, Larrigue, S, J F Delfraissy, J M Ragnaud, Perpoint, T, N Kiorza, L Richier, Treluyer, Jean-Marc, Ragnaud, J, Adda, A, Tattevin, P, T Allègre, Chapplain, J, Bouillon, M, Abgueguen, P, A Joulié, Varan, M, P Tattevin, J D Lelievre, C Charlier, S Caldato, Y Debab, M Lafaurie, Boibieux, A, B Hoen, S Rehaiem, P H Consigny, Schlienger, I, A Aslan, C Mededji, Colin de Verdiere, N, Cuzin, L, Dellamonica, P, C Bourdeaux, M Obadia, Burty, C, G Hittinger, Pietri, M, Ajana, F, Mededji, C, Greder Belan, A, S Balkan, J M Chapplain, Y Quertainmont, P Morineau-Le-Houssine, S Abel, T May, F Guiroy, Bernard, L, Bernard, N, L Cotte, Bonnet, B, C Augustin Normand, Caron, F, C Brunet-François, Philip, G, C Chapuzet, N El Alami Talbi, Chermak, A, A S Lascaux, Salmon, D, Mounoury, O, F Jeanblanc, Christine Rouzioux, M Ruquet, de Castro, N +433 morecore +1 more sourceComparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort
Frontiers in Cellular and Infection MicrobiologyBackgroundDrug repurposing has become a widely adopted strategy to minimise research time, costs, and associated risks. Combinations of protease inhibitors such as lopinavir and darunavir with ritonavir have been repurposed as treatments for COVID-19 ...Dóra Paróczai, Dóra Paróczai, András Bikov, András Bikov, Andreea Blidaru, Emanuel Bobu, Ana Lascu, Ana Lascu, Cristian Ion Mot, Cristian Ion Mot, Stefan Mihaicuta, Stefan Mihaicuta, Stefan Frent, Stefan Frent +13 moredoaj +1 more sourceLong‐Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A Cost‐Effectiveness Analysis
Journal of the International AIDS Society, Volume 29, Issue 5, May 2026.ABSTRACT Introduction
In Brazil, men who have sex with men (MSM) and transgender women (TGW) remain heavily affected by HIV. Long‐acting pre‐exposure prophylaxis (LA PrEP) with injectable cabotegravir (CAB‐LA) or lenacapavir (LEN‐LA) is more effective at preventing HIV acquisition than oral PrEP.Wanyi Chen, Paula M. Luz, Anjali Srinivasan, Beatriz Grinsztejn, Justine A. Scott, Anne M. Neilan, Valdiléa G. Veloso, Caitlin M. Dugdale, Kenneth A. Freedberg +8 morewiley +1 more sourceTenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV
American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.ABSTRACT Background
Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse +5 morewiley +1 more sourceAntiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART [PDF]
, 2016 OBJECTIVES:
To describe the pattern of drug resistance at virological failure in the NEAT001/ANRS143 trial (first-line treatment with ritonavir-boosted darunavir plus either tenofovir/emtricitabine or raltegravir).Pearson M., Portilla J., Marcelin A. G., Furrer H. -J., Knellwolf A. -L., Levy Y., Di Perri G., Castelli F., Pahl C., Yeni P., Touloumi G., Pillay D., Behrens G., Touzeau G., Reynes J., Calvez V., Ammassari A., Hudson F., Tattevin P., Cabie A., Eid M., Schmidt R., Perre P., Pacciarini F., Reiss P., Vullo V., Lauriola M., Anagnostou O., Kummeling I., Richter C., Rouch E., Neau D., Ward D., Goujard C., George E. C., Paniego V., Johnson M., Smith C., Arribas J., Grarup J., Cursley A., Stellbrink H. -J., Saillard J., Lambert S., Teague A., Taylor K., Marcotullio S., Berenguer J., Boucher C., Taieb A., Moller N. F., Doroana M., Antunes F., Banhegyi D., Vandekerckhove L., Horban A., De Wit S., Christ I., Mulcahy F., Schmied B., Aldeguer J. L., Bonora S., Galli M., Tellez M. -J., Thalme A., Dupon M., Garcia J. G., Ramirez M., Nielsen B. R., Nieuwkerk P., Perno C. F., Van Leeuwen R., Amieva H., Paraina F., Daikos G. L., Jessen H., Mallon P., Williams I., Spencer-Drake C., Mathiesen L., Jean D., Volny-Anne A., Yazdan Y., Raffi F., Unger S., Thiebaut R., Richert L., Andreoni M., Domingo P., Manting C., Fatkenheuer G., Nguyen B. -Y., Katlama C., Couffin-Cadiergues S., White E., Larsen E. M., Miralles M. P., Obadia M., Weiss L., Ghosn J., Cotarelo M., Sarmento-Castro R., Hatzakis A., Mazzotta F., Gisslen M., Cheret A., Joensen Z. M., Massella M., Franquet X., Maltez F., Angus B., Schmidt R. E., Torok E., Moreno S., Soriano V., Leavitt R., Paton N., Diallo A., Miller V., Hoppe A., Bucciardini R., Quercia R., Vetter N., Le Moing V., Mocroft A., Schwimmer C., Braggion M., Monforte A. D., Moecklinghoff C., Codina J. M. L., Jensen K., Moyano B., Babiker A. G., Jakobsen M. -L., Wit F. W. N. M., Florence E., Carlo T., West B., Esteban H., Dedes N., Arnault F., Lazzarin A., Lathouwers D., Goebel F., Papadopoulos A., Esser S., Castagna A., Girbau I., Chene G., Leen C., Boucherie C., Gatell J. M., Pearce G., Van Eeden A., Ewings F., Rieger A., Hoffmann C., Yllescas M., Termote M., Prins J., Metro A., Spire B., Marquez M., Verhagen D., Wallet C., Allavena C., Antinori A., Piroth L., Colasanti V., Gioukari V., Girard P. -M., Morlat P., Boffito M., Soussi M., Jansson P. O., Gey D., Plettenberg A., Winston A., Palmisano L., Stoehr W., Binelli A., Sasieni P., Odermarsky M., Sanchez I., Vella S., Reilev S. S., Dodds W., Mendy B. Y., Kowalska J., Jensen B. G., Skoutelis A., Muller N. J., Wittkop L., Gatell J., Herieka E., Larsen E. F. M., Flepp M., Fragola V., Barea C., Ragnaud J. M., Blaxhult A., Russell C., Knobel H., Dunn D., Fischer A., Clotet B., Rogatto F., Foca E., Boyd M. A., Autran B., Gompels M., Sandstrom E., Saiz C., Stephan C., Molina J. -M., Murri R., Peto T., Collins S., Schwarze S., Aagaard B., Kaur N., Zucman D., Marcelin A. -G., Pozniak A., Rockstroh J., Aznar E., Gerstoft J., Post F., Fox J., Lambert-Niclot S., De La Serna J. I. B., Palmisiano L. +231 morecore +5 more sourcesDarunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals [PDF]
, 2009 Darunavir is the most recently licensed protease inhibitor currently used in treatment-experienced HIV-infected individuals. Our objective was to determine darunavir concentrations in cerebrospinal fluid (CSF) and plasma in subjects receiving ...Price, R. W., De Meulder, M, Timmerman, P, Izadkhasthi, Arash,, Gisslén, Magnus,, Yilmaz, Aylin,, Mallon, PW +6 morecore 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation
HIV Research & Clinical Practice, 2020 Antiretroviral therapies have been tested with the goal of maintaining virological suppression with a particular attention in limiting drug-related toxicity.Valentina Di Cristo, Fulvio Adorni, Renato Maserati, Marco Annovazzi Lodi, Giuseppe Bruno, Paolo Maggi, Anna Volpe, Paola Vitiello, Clara Abeli, Stefano Bonora, Micol Ferrara, Maria Vittoria Cossu, Maria Letizia Oreni, Elisa Colella, Stefano Rusconi +14 moredoaj +1 more sourceConsiderations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia
Haemophilia, Volume 32, Issue 3, Page 584-592, May/June 2026.ABSTRACT Introduction
There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg +5 morewiley +1 more sourceMechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance
mBio, 2018 Darunavir (DRV) has bimodal activity against HIV-1 protease, enzymatic inhibition and protease dimerization inhibition, and has an extremely high genetic barrier against development of drug resistance. We previously generated a highly DRV-resistant HIV-1 Manabu Aoki, Debananda Das, Hironori Hayashi, Hiromi Aoki-Ogata, Yuki Takamatsu, Arun K. Ghosh, Hiroaki Mitsuya +6 moredoaj +1 more source
